Trial Profile

Safety of SCH 527123 in Subjects With Neutrophilic Asthma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navarixin (Primary)
Indications Asthma
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme; Schering-Plough

Most Recent Events

01 Jul 2012 Results published in Clinical and Experimental Allergy.
28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
19 May 2010 Results will be presented at the 106th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com